| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2007PNAS..10419936M |
| P356 | DOI | 10.1073/PNAS.0707498104 |
| P932 | PMC publication ID | 2148401 |
| P698 | PubMed publication ID | 18077425 |
| P5875 | ResearchGate publication ID | 5771998 |
| P50 | author | Daniel Haber | Q5217393 |
| Ultan McDermott | Q39992201 | ||
| Shyamala Maheswaran | Q89582233 | ||
| Patricia Greninger | Q91735291 | ||
| Nathanael Gray | Q28112823 | ||
| P2093 | author name string | Angela Tam | |
| Heidi Archibald | |||
| Jeffrey Settleman | |||
| Raffaella Sordella | |||
| A John Iafrate | |||
| Lisa Drew | |||
| Clara Montagut | |||
| Mark G Erlander | |||
| Xiao-Jun Ma | |||
| Sreenath V Sharma | |||
| Hensin Tsao | |||
| Jeffrey G Supko | |||
| Diana Lee | |||
| Lindsey E Ulkus | |||
| Jennifer Lamb | |||
| Lori Dowell | |||
| S Michael Rothenberg | |||
| Raul Raudales | |||
| Ching Ni Njauw | |||
| Jeff H Hanke | |||
| P2860 | cites work | Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients | Q46624747 |
| Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study | Q46630310 | ||
| Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. | Q46813416 | ||
| Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. | Q53569591 | ||
| Gene amplification in gastric and esophageal adenocarcinomas | Q68920865 | ||
| Gefitinib-sensitizing mutations in esophageal carcinoma | Q83364741 | ||
| KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 | ||
| Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 | Q24541450 | ||
| Cluster analysis and display of genome-wide expression patterns | Q24644463 | ||
| A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes | Q24647928 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Guilty as charged: B-RAF is a human oncogene | Q28288202 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Where next for gefitinib in patients with lung cancer? | Q36496065 | ||
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 | ||
| Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer | Q36732046 | ||
| Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival | Q38441644 | ||
| P433 | issue | 50 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell line | Q21014462 |
| P304 | page(s) | 19936-19941 | |
| P577 | publication date | 2007-12-06 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling | |
| P478 | volume | 104 |
| Q33934987 | A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation |
| Q33742159 | A chemical and phosphoproteomic characterization of dasatinib action in lung cancer |
| Q29614275 | A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations |
| Q33978771 | A gene-alteration profile of human lung cancer cell lines. |
| Q30485093 | A mouse model for EML4-ALK-positive lung cancer |
| Q28480605 | A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation |
| Q39557213 | A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. |
| Q34061522 | A structure-guided approach to creating covalent FGFR inhibitors |
| Q42081770 | Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency |
| Q37628915 | Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation |
| Q38911199 | Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers |
| Q53264472 | Advances in the preclinical testing of cancer therapeutic hypotheses |
| Q39037450 | An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics |
| Q38752000 | An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling |
| Q92510255 | An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines |
| Q38673641 | An esophageal squamous cell carcinoma classification system that reveals potential targets for therapy |
| Q38275613 | An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. |
| Q39308117 | Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors |
| Q38944582 | Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma |
| Q37411178 | Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy |
| Q28729071 | Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells |
| Q36351612 | Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. |
| Q61812767 | Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells |
| Q37204679 | Applications of genomics in melanoma oncogene discovery |
| Q30490446 | Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia |
| Q47644139 | Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. |
| Q37715399 | Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer |
| Q27851610 | BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation |
| Q37581008 | CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma |
| Q29615032 | COT drives resistance to RAF inhibition through MAP kinase pathway reactivation |
| Q26800337 | Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine |
| Q89622556 | Case of Hereditary Papillary Renal Cell Carcinoma Type I in a Patient With a Germline MET Mutation in Russia |
| Q37503954 | Cell line modeling for systems medicine in cancers (review). |
| Q37714306 | Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents |
| Q38125434 | Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGF/MET–Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective |
| Q64993340 | Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer. |
| Q37234005 | Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. |
| Q38801748 | Chemical probes: The many genes of drug mechanism |
| Q38639762 | Chemotherapy for hepatocellular carcinoma: The present and the future |
| Q36698868 | Collections of simultaneously altered genes as biomarkers of cancer cell drug response |
| Q37039879 | Comparison and validation of genomic predictors for anticancer drug sensitivity |
| Q28541231 | Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use |
| Q27316921 | Cortactin Phosphorylated by ERK1/2 Localizes to Sites of Dynamic Actin Regulation and Is Required for Carcinoma Lamellipodia Persistence |
| Q36363613 | Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology |
| Q36971972 | Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification |
| Q41483011 | Design and synthesis of a novel tyrosine kinase inhibitor template |
| Q39277022 | Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase |
| Q54272422 | Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer |
| Q21131727 | Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy |
| Q30546921 | Differential Determinants of Cancer Cell Insensitivity to Antimitotic Drugs Discriminated by a One-Step Cell Imaging Assay |
| Q36697241 | Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon |
| Q50904409 | Differential regulation and synthetic lethality of exclusive RB1 and CDKN2A mutations in lung cancer. |
| Q33913913 | Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines |
| Q26799900 | Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance |
| Q38609721 | EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks |
| Q34782417 | EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation |
| Q39971699 | Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma |
| Q37249978 | ErbBs in lung cancer |
| Q91949994 | Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer |
| Q46296016 | Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery |
| Q34255055 | Exploiting genetic complexity in cancer to improve therapeutic strategies |
| Q35182422 | Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition |
| Q28252845 | Factors underlying sensitivity of cancers to small-molecule kinase inhibitors |
| Q27851615 | Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. |
| Q36062493 | Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent |
| Q37999073 | Functional drug-gene interactions in lung cancer. |
| Q34313686 | Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells |
| Q35698574 | HCC and angiogenesis: possible targets and future directions |
| Q30384542 | Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. |
| Q30414265 | Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition |
| Q33623110 | High-resolution network biology: connecting sequence with function |
| Q23058134 | High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines |
| Q37135359 | High-throughput kinase profiling as a platform for drug discovery |
| Q36545498 | IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide |
| Q83384990 | Impact of Genomics on Personalized Cancer Medicine |
| Q52659649 | Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. |
| Q38646272 | Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization. |
| Q33676812 | In vitro clinical trials: the future of cell-based profiling |
| Q37696682 | Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors |
| Q28479198 | Induction of stable drug resistance in human breast cancer cells using a combinatorial zinc finger transcription factor library |
| Q37295112 | Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program |
| Q33517983 | Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug? |
| Q34797680 | Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery |
| Q33950522 | Integration and analysis of genome-scale data from gliomas |
| Q52318134 | Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. |
| Q42611489 | Large-Scale Drug Screens Support Precision Medicine |
| Q34265511 | Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action |
| Q39861042 | Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors |
| Q33849248 | Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy |
| Q30437229 | Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling |
| Q37487153 | Lung cancer biology: a genetic and genomic perspective. |
| Q27777362 | MEK1 mutations confer resistance to MEK and B-RAF inhibition |
| Q64077351 | MET overexpression and activation favors invasiveness in a model of anaplastic thyroid cancer |
| Q37811895 | MET signalling: principles and functions in development, organ regeneration and cancer |
| Q36653537 | Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes. |
| Q35961180 | Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors |
| Q33783108 | Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients |
| Q57170070 | Modeling Endometrial Cancer: Past, Present, and Future |
| Q39456721 | Modeling Normal and Disordered Human Hematopoiesis |
| Q36828371 | Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy |
| Q38118791 | Molecular approaches towards development of purified natural products and their structurally known derivatives as efficient anti-cancer drugs: Current trends |
| Q34534164 | Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT |
| Q33828409 | Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy |
| Q58614572 | Molecular prescreening to select patient population in early clinical trials |
| Q91105875 | Network-based Biased Tree Ensembles (NetBiTE) for Drug Sensitivity Prediction and Drug Sensitivity Biomarker Identification in Cancer |
| Q36622817 | Noncovalent wild-type-sparing inhibitors of EGFR T790M |
| Q33755962 | Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-Met gene |
| Q35902144 | Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells |
| Q37828536 | Novel mitogen-activated protein kinase kinase inhibitors |
| Q28265862 | Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics |
| Q37966378 | Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC) |
| Q36762385 | Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment |
| Q28483092 | Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame |
| Q36090684 | Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. |
| Q28083032 | Organoid development in cancer genome discovery |
| Q37690136 | Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors |
| Q33717395 | PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models |
| Q28240702 | PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR |
| Q24339394 | Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms |
| Q34578584 | Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer |
| Q37301452 | Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection |
| Q38711090 | Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells |
| Q37866945 | Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers |
| Q40153764 | Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing. |
| Q39616531 | Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihy |
| Q61804782 | Predict drug sensitivity of cancer cells with pathway activity inference |
| Q28548616 | Predicting Anticancer Drug Responses Using a Dual-Layer Integrated Cell Line-Drug Network Model |
| Q37209222 | Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions |
| Q91214765 | Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations |
| Q35024682 | Prediction of individual response to anticancer therapy: historical and future perspectives |
| Q37814680 | Protein kinase signaling networks in cancer |
| Q30976077 | Publisher’s Note:Abstraction for data integration:Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction |
| Q29616828 | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF |
| Q39114003 | RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib |
| Q35146597 | RON(MST1R)is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma |
| Q36390438 | Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status |
| Q42204869 | Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine |
| Q37262314 | Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment |
| Q38770137 | Reproducible pharmacogenomic profiling of cancer cell line panels. |
| Q34371882 | Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth |
| Q35928137 | Resistance to the c-Met inhibitor KRC-108 induces the epithelial transition of gastric cancer cells |
| Q36643409 | Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations |
| Q57050008 | Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation |
| Q39540918 | STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. |
| Q35051588 | Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors |
| Q49068138 | Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming. |
| Q39194466 | Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer |
| Q38805800 | Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer |
| Q27660495 | Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function |
| Q35193504 | Soluble c-Met is a reliable and sensitive marker to detect c-Met expression level in lung cancer |
| Q41883228 | Somatic mutaome profile in human cancer tissues |
| Q30278774 | Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status |
| Q37127423 | Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy |
| Q39348601 | Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors |
| Q39110584 | Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAFV600E inhibitors |
| Q39277031 | Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors |
| Q28486051 | Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines |
| Q33575305 | Systematic analysis of genotype-specific drug responses in cancer |
| Q29547695 | Systematic identification of genomic markers of drug sensitivity in cancer cells |
| Q37851009 | Taming the dragon: genomic biomarkers to individualize the treatment of cancer. |
| Q64886353 | Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib. |
| Q37988604 | Targeted therapy of hepatocellular carcinoma: present and future. |
| Q36903802 | Targeting MYCN in neuroblastoma by BET bromodomain inhibition |
| Q33893019 | Targeting the cancer kinome through polypharmacology |
| Q33584823 | Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe |
| Q29547693 | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity |
| Q35068059 | The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells |
| Q45082632 | The evolving landscape of therapeutic drug development for hepatocellular carcinoma |
| Q37389768 | The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer |
| Q34291977 | The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer |
| Q36582552 | The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer |
| Q82941854 | Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin |
| Q55067935 | Towards an integrated understanding of epidermal growth factor receptor biology for radiation therapy: integrins enter. |
| Q34125699 | Towards patient-based cancer therapeutics |
| Q37890867 | Towards systematic functional characterization of cancer genomes |
| Q47760026 | Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook |
| Q26801410 | Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics |
| Q89651597 | Turning liabilities into opportunities: Off-target based drug repurposing in cancer |
| Q37408903 | Tyrosine phosphorylation: thirty years and counting |
| Q28546245 | Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors |
| Q27320602 | Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer |
| Q27852401 | Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth |
| Q34032640 | Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. |
| Q27012684 | Will kinase inhibitors make it as glioblastoma drugs? |
| Q37962905 | c-MET as a potential therapeutic target and biomarker in cancer |
| Q39459195 | p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition |
| Q89082200 | β-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer |
Search more.